A detailed history of Pacer Advisors, Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 940 shares of BEAM stock, worth $23,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares
940
Previous 1,134 17.11%
Holding current value
$23,030
Previous $37,000 40.54%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$21.22 - $32.66 $4,116 - $6,336
-194 Reduced 17.11%
940 $22,000
Q1 2024

May 10, 2024

BUY
$23.46 - $45.07 $26,603 - $51,109
1,134 New
1,134 $37,000
Q2 2021

Jul 21, 2021

SELL
$64.12 - $128.71 $50,718 - $101,809
-791 Closed
0 $0
Q1 2021

Apr 05, 2021

SELL
$71.28 - $120.75 $52,889 - $89,596
-742 Reduced 48.4%
791 $63,000
Q4 2020

Jan 20, 2021

BUY
$22.24 - $95.63 $34,093 - $146,600
1,533 New
1,533 $125,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.72B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.